Literature DB >> 31124840

Polymodal Mechanism for TWIK-Related K+ Channel Inhibition by Local Anesthetic.

Mahmud Arif Pavel1,2, Hae-Won Chung1,2, E Nicholas Petersen1,2, Scott B Hansen1,2.   

Abstract

BACKGROUND: Local anesthetics cause reversible block of pain and robustly inhibit TWIK-related K channel (TREK-1) currents. Before local anesthesia onset, injection of local anesthetics can cause unwanted transient pain. TREK-1 is an anesthetic-sensitive potassium channel that when inhibited produces pain. A disordered C-terminal loop of TREK-1 is thought to contribute to anesthetic sensitivity, but the molecular basis for TREK-1 inhibition by local anesthetics is unknown. Phospholipase D2 (PLD2) is an enzyme that produces phosphatidic acid (PA) required for TREK-1 activation and also binds to the channel's C terminus.
METHODS: Here, we use biophysical and cellular techniques to characterize direct and indirect lipid-mediated mechanism for TREK-1 inhibition (respectively). We characterized direct binding of local anesthetic to TREK-1 by reconstituting the purified channel into artificial membranes and measuring ion flux. We characterized indirect PA-mediated inhibition of TREK-1 by monitoring lipid production in live whole cells using a fluorescent PLD2 product release assay and ion channel current using live whole-cell patch-clamp electrophysiology. We monitored anesthetic-induced nanoscale translocation of PLD2 to TREK-1 channels with super-resolution direct stochastic reconstruction microscopy (dSTORM).
RESULTS: We find local anesthetics tetracaine, lidocaine, and bupivacaine directly bind to and inhibit PLD2 enzymatic activity. The lack of PLD2 activity indirectly inhibited TREK-1 currents. Select local anesthetics also partially blocked the open pore of TREK-1 through direct binding. The amount of pore block was variable with tetracaine greater than bupivacaine and lidocaine exhibiting a minor effect. Local anesthetics also disrupt lipid rafts, a mechanism that would normally activate PLD2 were it not for their direct inhibition of enzyme catalysis.
CONCLUSIONS: We propose a mechanism of TREK-1 inhibition comprised of (1) primarily indirect PLD2-dependent inhibition of lipid catalysis and (2) limited direct inhibition for select local anesthetics through partial open pore block. The inhibition through PLD2 explains how the C terminus can regulate the channel despite being devoid of structure and putative binding sites for local anesthetics.

Entities:  

Year:  2019        PMID: 31124840     DOI: 10.1213/ANE.0000000000004216

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  5 in total

Review 1.  Disruption of palmitate-mediated localization; a shared pathway of force and anesthetic activation of TREK-1 channels.

Authors:  E Nicholas Petersen; Mahmud Arif Pavel; Hao Wang; Scott B Hansen
Journal:  Biochim Biophys Acta Biomembr       Date:  2019-10-28       Impact factor: 3.747

2.  N-Glycosylation of TREK-1/hK2P2.1 Two-Pore-Domain Potassium (K2P) Channels.

Authors:  Felix Wiedmann; Daniel Schlund; Francisco Faustino; Manuel Kraft; Antonius Ratte; Dierk Thomas; Hugo A Katus; Constanze Schmidt
Journal:  Int J Mol Sci       Date:  2019-10-20       Impact factor: 5.923

3.  Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture.

Authors:  Zixuan Yuan; Mahmud Arif Pavel; Hao Wang; Jerome C Kwachukwu; Sonia Mediouni; Joseph Anthony Jablonski; Kendall W Nettles; Chakravarthy B Reddy; Susana T Valente; Scott B Hansen
Journal:  Commun Biol       Date:  2022-09-14

4.  Studies on the mechanism of general anesthesia.

Authors:  Mahmud Arif Pavel; E Nicholas Petersen; Hao Wang; Richard A Lerner; Scott B Hansen
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-28       Impact factor: 11.205

Review 5.  Structural Insights into the Mechanisms and Pharmacology of K2P Potassium Channels.

Authors:  Andrew M Natale; Parker E Deal; Daniel L Minor
Journal:  J Mol Biol       Date:  2021-04-20       Impact factor: 5.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.